New Amsterdam Sciences
Private Company
Funding information not available
Overview
New Amsterdam Sciences is a private, preclinical-stage biotech focused on an anti-inflammatory platform targeting reactive oxygen species (ROS)-driven inflammation. Its pipeline is broad and early-stage, spanning human therapeutics for rheumatoid arthritis, COVID-19, influenza, and neurodegenerative diseases like Progressive Supranuclear Palsy, as well as programs in animal health and radiomitigation. The company appears to be pre-revenue, relying on private investment to advance its research, and faces significant execution risk due to its early technology stage and wide-ranging pipeline focus.
Technology Platform
Anti-inflammatory platform targeting oxidative stress (ROS)-driven inflammation using small molecule therapies.
Funding History
1Opportunities
Risk Factors
Competitive Landscape
Each therapeutic area is intensely competitive. In rheumatoid arthritis, numerous biologic and targeted synthetic DMARDs exist. The COVID-19/influenza space is crowded with antivirals and vaccines. The PSP space, while niche, has active clinical programs from larger biopharma. Differentiation will require robust clinical data.